{"status": "OK", "response": {"docs": [{"type_of_material": "News", "blog": [], "news_desk": "National Desk", "lead_paragraph": "The Clinton Administration has told state officials that it intends to require their Medicaid programs to pay for medically approved uses of the impotence drug Viagra. But states could limit the number of pills and prescriptions for the drug. The plans have upset state officials, who contend that decisions on the coverage of Viagra should be left to the states, which share Medicaid costs with the Government.", "headline": {"main": "White House Plans Medicaid Coverage Of Viagra by States"}, "abstract": "Clinton Administration tells state officials that it intends to require their Medicaid programs to pay for medically approved uses of impotence drug Viagra; says states can limit number of pills and prescriptions for drug; plans have upset state officials, who contend that decisions on coverage of Viagra should be left to states, which share Medicaid costs with Government; Pfizer Inc, maker of Viagra, suggests covering 10 pills a month if states insist on limit (M)", "print_page": "1", "word_count": 1015, "_id": "4fd1deac8eb7c8105d722ef7", "snippet": "The Clinton Administration has told state officials that it intends to require their Medicaid programs to pay for medically approved uses of the impotence drug Viagra. But states could limit the number of pills and prescriptions for the drug.    The...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/1998/05/28/us/white-house-plans-medicaid-coverage-of-viagra-by-states.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "CLINTON, BILL"}, {"name": "organizations", "value": "PFIZER INC"}, {"name": "subject", "value": "SEX"}, {"name": "subject", "value": "STATES (US)"}, {"name": "subject", "value": "HEALTH INSURANCE"}, {"name": "subject", "value": "IMPOTENCE"}, {"name": "subject", "value": "MEDICAID"}, {"name": "subject", "value": "VIAGRA (DRUG)"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Robert", "lastname": "PEAR"}], "original": "By ROBERT PEAR"}, "document_type": "article", "pub_date": "1998-05-28T00:00:00Z", "section_name": "Front Page; Health; U.S."}, {"type_of_material": "News", "blog": [], "news_desk": "National Desk", "lead_paragraph": "A new study provides the first evidence that people with average cholesterol levels can substantially reduce their risk of heart attack by taking a drug that drives their cholesterol levels even lower. The study, financed by Merck & Company, involved 6,605 middle-aged-to-elderly men and women, half of whom took Merck's powerful and expensive cholesterol-lowering drug, lovastatin; the rest took a dummy pill. After five years, those who had taken lovastatin had had 37 percent fewer heart attacks and other serious signs of heart disease than those who had taken the placebo.", "headline": {"main": "A Broader Benefit Is Found in a Drug To Cut Cholesterol"}, "abstract": "New study financed by Merck & Co, drug manufacturer, provides first evidence that people with average cholesterol levels can substantially reduce risk of heart attack by taking lovastatin, drug that drives cholesterol level even lower; found middle-aged to elderly men who took lovastatin over five-year period had 37 percent fewer heart attacks and other serious signs of heart disease than those who had taken placebo; researchers say if findings are put into practice, population eligible for cholesterol-lowering drugs would quadruple to eight million people, from two million who currently qualify for drug treatment; while medical experts say study was well conducted and that its results are solid, results are opening debate among some who question how hard people should try to reduce cholesterol levels below what is considered acceptable, and how much nation should pay to save few more people from heart disease (M)", "print_page": "1", "word_count": 1536, "_id": "4fd1deb38eb7c8105d7234f0", "snippet": "A new study provides the first evidence that people with average cholesterol levels can substantially reduce their risk of heart attack by taking a drug that drives their cholesterol levels even lower.    The study, financed by Merck & Company,...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/1998/05/27/us/a-broader-benefit-is-found-in-a-drug-to-cut-cholesterol.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "organizations", "value": "MERCK & CO INC"}, {"name": "subject", "value": "HEART"}, {"name": "subject", "value": "AGE (CHRONOLOGICAL)"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "AGED"}, {"name": "subject", "value": "LOVASTATIN (DRUG)"}, {"name": "subject", "value": "RESEARCH"}, {"name": "subject", "value": "CHOLESTEROL"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Gina", "lastname": "KOLATA"}], "original": "By GINA KOLATA"}, "document_type": "article", "pub_date": "1998-05-27T00:00:00Z", "section_name": "Front Page; Health; U.S."}, {"type_of_material": "News", "blog": [], "news_desk": "Science Desk", "lead_paragraph": "FOR weeks, a barrage of good news about cancer in people has come from scientists and public health officials. In March, the Government announced the first drop in the number of new cancer cases since the 1930's and a continued decline in cancer deaths.", "headline": {"main": "Good News From the Front in the War Against Cancer", "kicker": "THE DOCTOR'S WORLD"}, "abstract": "Lawrence K Altman reports that 18,000 cancer specialists attending annual meeting of American Society of Clinical Oncology in Los Angeles spoke enthusiastically about reports reflecting cutting edge of research; with standard cell-killing chemotherapy pushed to its limits, oncologists predict that next wave of therapies is most likely to come from laboratory findings about genetic defects that are presumed to give rise to cancer; table shows mortality rates and survival rates for 10 most deadly cancers (L)", "print_page": "3", "word_count": 1699, "_id": "4fd20c648eb7c8105d77bc44", "snippet": "FOR weeks, a barrage of good news about cancer in people has come from scientists and public health officials.    In March, the Government announced the first drop in the number of new cancer cases since the 1930's and a continued decline in cancer...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/1998/05/26/science/the-doctor-s-world-good-news-from-the-front-in-the-war-against-cancer.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "organizations", "value": "AMERICAN SOCIETY OF CLINICAL ONCOLOGY"}, {"name": "subject", "value": "COLON"}, {"name": "subject", "value": "PROSTATE GLAND"}, {"name": "subject", "value": "STOMACH"}, {"name": "subject", "value": "BRAIN"}, {"name": "subject", "value": "BREAST"}, {"name": "subject", "value": "LEUKEMIA"}, {"name": "subject", "value": "GENETICS AND HEREDITY"}, {"name": "subject", "value": "CANCER"}, {"name": "subject", "value": "LUNGS"}, {"name": "subject", "value": "OVARIES"}, {"name": "subject", "value": "NON-HODGKIN'S LYMPHOMA"}, {"name": "subject", "value": "PANCREAS"}], "byline": {"person": [{"qualifier": "M.D", "firstname": "Lawrence", "middlename": "K.", "lastname": "ALTMAN", "rank": 1, "role": "reported", "organization": ""}], "original": "By LAWRENCE K. ALTMAN, M.D"}, "document_type": "article", "pub_date": "1998-05-26T00:00:00Z", "section_name": "Science; Health"}], "meta": {"hits": 3, "offset": 0, "time": 210}}, "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}